Issue link: https://beckershealthcare.uberflip.com/i/498463
25 Becker's 13th Annual Spine, Orthopedic and Pain Management-Driven ASC Conference + The Future of Spine - call (800) 417-2035 Mark Flood, DO (Laser Spine Institute, Tampa, Fla.). Dr. Flood is the chief of surgical innova- tion and an orthopedic spine surgeon at the Laser Spine Institute in Tampa, Fla. He is an innovator with the RegenaDISC system, which uses stem cell therapy and low-level laser spinal decompression to repair discs. Gary Ghiselli, MD (Denver Spine Surgeons). Dr. Ghiselli was the principal investigator in the FDA- cleared adult stem cell study testing the novel treat- ment for chronic low back pain, which began in early 2012. The study used mesenchymal precursor cells to be injected directly into the lumbar disc. Sanjitpal Singh Gill, MD (Medical Group of the Carolinas, Spartanburg, S.C.). Dr. Gill is an assis- tant professor in the department of engineering at Clemson University where he is researching bio- logic disc replacement. He has a special interest in treating athletes and was head team physician for the United States Adaptive Ski Team and pro- vided medical coverage for the United States Pro Cycling championships. Steven Glassman, MD (Norton Leatherman Spine Center, Louisville, Ky.). Dr. Glassman is a member of the board of directors for the Scoliosis Research Society and has been a program chair for the North American Spine Society. He focuses on patient-based outcomes and cost-effectiveness for spinal surgery, as well as the role of biologics in spinal fusion. Roger Hartl, MD (Weill Cornell Brain and Spine Center, New York City). Dr. Hartl is currently investigating two biological materials in animal models: the tissue-engineered intervertebral discs and collagen gel. The tissue-engineered discs are composites of collagen gel harvested from rat tail tendons and seeded with intervertebral discs from sheep spines. He is director of spinal surgery and neurotrauma at Weill Cornell Brain and Spine Center. Robert F. Heary, MD (Neurological Institute of New Jersey, Newark). Dr. Heary is the director of the Spine Center at the Neurological Institute of New Jersey. His major areas of interest include minimally invasive spine surgery, spine injury, spine tumors and spinal deformity. He has con- ducted endowed research on the effects of injured neurons on mesenchymal stem cells. Michael Heggeness, MD (KU School of Medi- cine, Witchita, Kan.). In addition to his medi- cal degree, Dr. Heggeness completed his PhD in biochemistry from the University of California at San Francisco. His research interests include the anatomy and biomechanics of the spine, nerve investigations and developing new techniques for tissue engineering of bone that seeks to use mo- lecular genetic techniques to stimulate fusion and healing of fractures. Patrick C. Hsieh, MD (Keck Medicine of USC, Los Angeles). Dr. Hsieh is involved in several research projects, including the development of primary cell lines and xenograft model for Chor- doma. He is on the forefront of the shift in tech- nology for restorative care and using stem cells for spinal cord injury. Dr. Hsieh is director of the minimally invasive spine program at the USC Spine Center. Wellington Hsu, MD (Northwestern Univer- sity Feinberg School of Medicine, Chicago). Dr. Hsu is director of the Professional Athlete's Spine Initiative, which compiles data on athletes who undergo treatment for spinal conditions. At Northwestern, Dr. Hsu heads the Laboratory for Regenerative Technologies. He has a research in- terest in tissue engineering and bone graft substi- tutes for spinal fusion. Richard A. Hynes, MD (The BACK Center, Mel- bourne, Fla.). Dr. Hynes has participated in nu- merous FDA-approved studies and has a profes- sional interest in biologics and the use of stem cells in spinal surgery. Along with his clinical work, Dr. Hynes has served as a director of TXE- DAKA, a charity that helps low-income individu- als gain access to the medical care they need. Stanley Jones, MD (SpineCare, Houston). Dr. Jones earned national recognition for performing spine surgery using stem cells on Texas Governor and former Republican candidate for the presi- dential nomination Rick Perry. The procedure, developed by RNL BIO, a company specializing AnticipAte chAnge. We do. 2013 ® 636.273.6711 | www.nationalASCbilling.com the ASc Revenue cycle. It's all we do. It's all we think about. And it shows. Named one of the world's best outsourcing service providers two years in a row. – Fortune Magazine 2013